# Effects of daily variation in outdoor particulates and ambient acid species in normal and asthmatic children

D J Ward, K T Roberts, N Jones, R M Harrison, J G Ayres, S Hussain, S Walters

.....

Thorax 2002;57:489-502

See end of article for authors' affiliations

Correspondence to: Professor J G Ayres, Department of Respiratory Medicine, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK; ayresj@heartsol.wmids.nhs.uk

Revised version received 26 November 2001 Accepted for publication 12 December 2001 **Background:** Evidence suggests that the respiratory health of children may be adversely affected by daily variation in outdoor pollutants, particularly ozone and particulates. However, data from the UK are sparse and the contribution of different particulate fractions and acid species, together with the identification of those individuals most at risk, are not clear.

**Methods:** One hundred and sixty two 9 year old children were enrolled from two inner city locations and recorded daily symptoms and twice daily peak expiratory flow (PEF) over 8 week periods in the winter and summer. Their results were analysed with daily pollutant levels at appropriate lags using regression models which corrected for trends, weather, pollen, and autocorrelation.

**Results:** Pollutant levels were generally low, especially in the summer. Multiple statistically significant associations were noted between health outcomes and pollutant concentrations, but no consistent patterns in identified effects were apparent between pollutants, lags, direction of observed effect, or location. There was no evidence to suggest that subgroups with atopy or pre-existing wheeze are more sensitive to pollutant effects.

**Conclusion:** These data do not suggest that adverse health outcomes are associated with daily variation in health effects. No evidence was found to indicate that particulates or individual acid and anion species are more closely related to adverse health outcomes than other pollutants.

A ir pollution is generally recognised to affect human health, even below current regional standards.<sup>1</sup> In children, short term falls in lung function and increases in respiratory symptoms have been related to daily variations in pollutant levels, including the mass concentration of particulates.<sup>2</sup> <sup>3</sup> Children with pre-existing respiratory disease may be more sensitive to such effects,<sup>4</sup> <sup>5</sup> although this observation may not translate simply to "asthma severity".<sup>6</sup> However, a recent European multicentre study of asthmatic children (Pollutant Effects on Asthmatic Children in Europe (PEACE)) failed to detect any consistent association between air pollutants and short term health effects, despite the wide range of climatic conditions and pollutant mixes encountered across the sites.<sup>7</sup>

The characteristics of particles responsible for their specific health effects are not known. Measures of particle acidity have been shown to produce similar health outcome relationships to particle mass measures.<sup>8</sup> One study has suggested that hospital admissions may be most closely related to particle acidity, sulphate content  $(SO_4^{2-})$  and small size,<sup>9</sup> but other studies report adverse effects of particulates in the absence of significant acidity.<sup>3</sup> Levels of individual acid and anion species, including nitrate  $(NO_3^{-})$ , nitric acid  $(HNO_3)$ , and ammonium  $(NH_4^+)$ , have also shown significant, albeit small, relationships with short term adverse respiratory health outcomes.<sup>10</sup>

This study aimed to characterise potential short term adverse respiratory effects of outdoor air pollutants on UK urban primary school children with and without chronic respiratory symptoms or an atopic phenotype. In addition, the study considered whether any such effects were more closely related to  $PM_{2.5}$  than to  $PM_{10}$  (mass concentration of particulates with mean aerodynamic diameter <2.5  $\mu$ m and 10  $\mu$ m, respectively) and to concentrations of individual acid and anion species than to particulate mass measures.

## **METHODS**

A time series "panel" study design was used" with two 8 week monitoring periods representing winter (13 January–10 March 1997) and summer (19 May–14 July 1997) conditions. Subjects were recruited from five primary schools in two urban locations—Birmingham, a major city in the English Midlands, and Sandwell, a large urban area contiguous with Birmingham—which were analysed separately. The schools selected were close to major motorways and congested city arterial roads. Study approval was obtained from the East Birmingham research and ethics committee.

#### Panel recruitment and monitoring

The panel comprised 9 year old children enrolled during September 1996. After giving written consent, parents completed a questionnaire detailing their child's respiratory symptoms, atopic illnesses, and relevant housing factors. Subjects were divided into subgroups on the basis of reported wheezing in the previous 12 months in the absence of a respiratory tract infection. Baseline spirometric tests and skin testing to common allergens (cat, dog, grass, trees, house dust mite, and cockroach) were performed. Children were considered atopic on the basis of at least one positive skin test (mean weal diameter at least 3 mm greater than negative control).

Children and teachers were instructed in peak expiratory flow (PEF) measurement and all subjects were issued with a PEF meter (Vitalograph Ltd, UK). The highest of three PEF readings at morning registration (08.45–09.00 hours) and at the end of the school day (15.30–15.45 hours) were recorded. At weekends parents were asked to ensure a reading at breakfast time and in mid-afternoon. Subjects were required to record medication taken each day and to respond to the following five questions:

- "Did you cough today?"
- "Were you ill today?"
- "Were you short of breath (SOB) today?"
- "Did you wake up last night with a cough or wheeze?"
- "Did you wheeze today?"

Diary cards were issued and collected weekly and inspected immediately for errors or omissions. Data were entered onto a

	Birmingham childre (n=104)	n Sandwell children (n=58)	Subgroup with recent wheezing (n=39)	Subgroup without recent wheezing (n=123)
Sex				
Girls	52 (50%)	24 (41%)	14 (36%)	62 (50%)
Boys	52 (50%)	34 (59%)	25 (64%)	61 (50%)
Ethnicity*				
ISC	9 (9%)	2 (3%)	4 (10%)	7 (6%)
Black	7 (7%)	2 (3%)	4 (10%)	5 (4%)
White	88 (85%)	51 (88%)	30 (77%)	109 (89%)
Other	0 (0%)	1 (2%)	0 (0%)	1 (1%)
Parental report of respiratory symptoms				
Wheezing ever	34 (33%)	23 (40%)	34 (87%)	23 (19%)
Wheezing in past 12 months	23 (22%)	16 (28%)	39 (100%)	0 (0%)
Diagnosed asthma	24 (23%)	20 (34%)	28 (72%)	16 (13%)
Nocturnal cough in past 12 months	27 (26%)	20 (34%)	21 (54%)	26 (21%)
Housing factors				
≥1 household smoker	53 (51%)	27 (47%)	17 (44%)	63 (52%)
Furry pets	72(69%)	35 (60%)	23 (59%)	84 (69%)
Gas cooking	85 (82%)	37 (64%)	31 (79%)	91 (75%)
Gas fire use	74 (71%)	40 (69%)	27 (69%)	87 (71%)
Damp housing (reported)	14 (13%)	6 (10%)	9 (23%)	11 (9%)
Baseline investigations				
Atopic (≥1 positive skin test)	27 (26%)	23 (40%)	19 (49%)	31 (25%)
Mean (SD) % predicted FEV1	98 (12.5)	98 (10.5)	96 (14.2)	99 (12.5)
Mean (SD) % predicted FVC	89 (13.3)	89 (13.8)	86 (15.4)	90 (12.8)

**Table 1** Characteristics of the 162 panel members (all aged 9 years by September 1996), of whom 39 (24%) were defined as having suffered recent wheezing on the basis of a parental report on questionnaire

spreadsheet by optical character recognition scanning (DRS Infotech, Milton Keynes, UK). Prior to analysis, PEF recordings were corrected for non-linear errors of the meters using an equation derived from the response of a sample of meters to a servo-controlled pump.<sup>12</sup>

#### **Environmental monitoring**

The five schools were near existing background urban air pollution monitoring stations, either as part of the National Automatic Urban and Rural Network or provided by local government. These stations measure nitrogen oxides (NO<sub>x</sub>, NO, NO<sub>2</sub>), sulphur dioxide (SO<sub>2</sub>), ozone, carbon monoxide (CO), and PM<sub>10</sub> as hourly averages. Measurements of PM<sub>10</sub> and PM<sub>25</sub> used TEOM instruments equipped with 2.5  $\mu$ m cyclone inserts operated at 50°C.13 At two sites denuders enabled measurement of ammonia (NH<sub>3</sub>) and acid gases (SO<sub>2</sub>, hydrochloric acid (HCl), and HNO<sub>3</sub>), chloride (Cl<sup>-</sup>), NO<sub>3</sub><sup>-</sup>, and NH<sub>4</sub><sup>+, 14 15</sup> Measurements of SO42-, NO3-, and Cl- were made by standard ion chromatographic methods, and of aerosol strong acid (H<sup>+</sup>) by aqueous extraction and determination of pH according to the method of Koutrakis and coworkers.<sup>16</sup> The samples were collected daily and stored under refrigeration for batch analysis.

The University of Birmingham Weather Service and the Pollen Research Unit, Worcester provided daily maximum, mean and minimum temperatures, mean relative humidity, barometric pressure, wind speed, and summer pollen counts.

## Statistical analysis

Analysis of data followed the methodology developed for the PEACE study.<sup>17</sup> Subjects who failed to record data on more than 22 days in each period (40%) were excluded because of inadequate data collection. The first two days of all PEF records were ignored to reduce potential training effects, and each subject's PEF record was transformed into daily deviations from their individual mean PEF for morning and afternoon separately. PEF data were analysed as the daily mean of individual deviations (ΔPEF), weighted according to the number of reporting children that day. Symptom data were analysed as the daily proportion of subjects reporting each symptom (% prevalent symptoms) or reporting a new episode of each symptom (% incident symptoms). For each day the denominator was defined as the number of children recording both morning and afternoon PEF.

Putative associations between environmental variables and health outcomes were initially explored using bivariate correlation (Pearson's correlation coefficient, r) and considered lags of 0-3 days and a 7 day prior mean. Final results were calculated using a linear regression approach for  $\Delta PEF$  and logistic regression for symptoms. Final effect estimates were then derived from  $\beta$  (regression) coefficients in models accounting for relevant confounding factors. For each outcome, terms correcting for trend, weather elements, autocorrelation within the model residuals, and a dummy variable indicating schooldays (versus weekends and holidays) were included. For ΔPEF, linear and square root trend terms were considered for inclusion to adjust for lung growth and potential training effects. For symptoms, linear, quadratic and higher order polynomial trend terms were considered.17 Weather and summer pollen variables were considered for inclusion at the lag resulting in the strongest association to the health outcome. The a priori hypothesis required linear trend, a temperature term, and a term correcting for first order autocorrelation to be included. Other trend and weather terms were included on the basis of examining the residual variance and goodness of fit  $(r^2)$ statistics. Terms correcting for higher order autocorrelation were included on the basis of visually examining the autocorrelation and partial autocorrelation functions of the model residuals. For comparability, both Birmingham and Sandwell models were required to contain the same terms, albeit at different lags for weather variables. Pooled results for the entire panel could then be derived for  $\Delta PEF$  and symptom outcomes by combing the effect estimate from each location after weighting by the inverse of its variance.

In addition to considering each panel as a whole, subgroups based on atopic status and a history of recent wheezing were analysed with the main pollutants of interest using the models identified for the whole panel to determine whether these children were at increased risk of adverse health effects.<sup>18</sup> In



Figure 1 Selected time plots of  $\Delta PEF$ , symptoms and pollutants for the winter (A, C) and summer (B, D) monitoring periods (data for Birmingham only shown).

addition to examining effect sizes in these groups, comparisons were also made with results from the remaining panel members.

### RESULTS

#### **Panel recruitment**

Consent was obtained in 162 of 264 eligible children (table 1). Four children were lost to the panel before the summer period. The subgroup with a history of recent wheezing comprised 39 subjects; sleep disturbance was reported in 13 of these (33%) and wheezing severe enough to limit speech in five (13%). No significant differences in the proportion of children with a history of recent wheezing were found between schools or sexes.

No differences in baseline spirometric subgroups based on a history of recent wheezing were recorded. Children with a such a history were significantly more likely to be labelled atopic than those without recent wheezing and were more likely to show specific reactions to house dust mite allergen, tree pollen, and cat dander (p<0.05).

#### Data collection from subjects

Morning PEF records were available for a median of 140/162 subjects in winter (87% response, range 106–159) and 126/158 in summer (79% response, range 93–142). In general, symptoms were more frequently recorded in the winter than the summer (fig 1), the most frequently reported symptom being cough. Inadequate data collection resulted in the exclusion of 14 and 20 children, respectively, from the winter and summer periods. Direct questioning determined whether a child possessed anti-asthma medication, but individual dosages were poorly recorded so these data were discarded.

# **Environmental results**

Wintertime pollutant levels were unexceptional and  $PM_{10}$  exceeded 40  $\mu$ g/m<sup>3</sup> on only four occasions (table 2 and fig 1). Such peaks were associated with increased oxides of nitrogen and SO<sub>2</sub>. A modest increase in ozone was seen in March. Poor weather meant that summer pollutant levels were generally low.  $PM_{10}$  exceeded 40  $\mu$ g/m<sup>3</sup> only in the final week (fig 1), associated with increased oxides of nitrogen. Acid and anion concentrations were especially low as conditions for their

 Table 2
 Median (range) of environmental variables for the winter (13 January–10

 March 1997) and summer (19 May–14 July 1997) monitoring periods

Environmental variable	Winter	Summer
NO <sub>2</sub> (ppb)	18.0 (4–35)	13.3 (3–29)
Ozone (ppb)	13.0 (2–33)	22.0 (10-41)
$PM_{10} (\mu g/m^3)$	21.5 (8–46)	18.7 (7–38)
$PM_{2.5} (\mu g/m^3)$	12.7 (4–37)	12.3 (5–28)
SO <sub>2</sub> (ppb)	5.4 (2-18)	4.7 (2-10)
$H^+$ (ng/m <sup>3</sup> )	8.6 (≤12.7)*	6.3 (≤7.6)*
$Cl^{-}(\mu g/m^{3})$	3.0 (0.9–7.3)	0.8 (0.3-5.1)
$HCl(\mu g/m^3)$	0.3 (0.0–1.7)	0.3 (0.0-1.0)
$HNO_3 (\mu g/m^3)$	0.5 (0.2–2.2)	1.1 (0.4–3.8)
$NH_3 (\mu g/m^3)$	5.6 (0.9-23.8)	4.2 (0.6-8.8)
$NH_4^+$ (µg/m <sup>3</sup> )	2.0 (0.2–15.5)	2.5 (0.5-7.1)
$NO_3^-$ (µg/m <sup>3</sup> )	3.6 (0.1–29.9)	3.5 (0.7–13.2)
$SO_4^{2-}$ (µg/m <sup>3</sup> )	2.4 (0.8–14.9)	3.8 (1.1–7.8)
Minimum temperature (°C)	2.5 (-3.5-8.1)	9.4 (2.1–14.1)
Mean temperature (°C)	5.5 (-1.0-9.9)	13.4 (8.1–19.1)
Maximum temperature (°C)	8.6 (1.5–13.3)	17.9 (10.6-25.5)
Relative humidity (%)	84 (67–96)	74 (47–92)
Barometric pressure (hPa/mb)	956 (923-977)	952 (926–966)
Wind speed (mph)	8 (2-18)	6 (3-15)

Levels indicate the 24 hour mean unless indicated otherwise and pollutant data averaged across up to five sites.

\*Median of days where levels exceeded the detectable limit, but most days (39/56 winter and 47/56 summer) were below this limit of approximately 5 ng/m<sup>3</sup>.

formation were unfavourable. Aerosol strong acidity (H<sup>+</sup>) levels were detectable on only 17 winter and 9 summer days and were therefore not analysed.

Multiple cross correlations were seen between pollutants for both the winter and summer periods. Very strong positive correlations between winter time  $PM_{10}$  and  $PM_{2.5}$  (r=0.93) were accompanied by similar relationships to NO<sub>2</sub> and, in the

negative direction, to ozone. These associations were especially strong for  $PM_{2.5}$  (r=0.88 and r=-0.83, respectively). Weaker associations were noted with SO<sub>2</sub>. Most individual acid and anion species also showed a strong degree of positive correlation with each other and the particulate mass measures ( $PM_{2.5}$ more than  $PM_{10}$ ). However, Cl<sup>-</sup>, HCl, HNO<sub>3</sub> and, to a lesser extent, H<sup>+</sup> were poorly associated with each other (except Cl<sup>-</sup>

**Table 3** Results of the final models for the entire panel during the winter period: estimated effect size (change in ΔPEF (l/min) or symptom odds per pollutant rise across interquartile range) and 95% confidence intervals (CI) for mass concentration of particulates and gaseous pollutants

	Lag						
Pollutant	0	1 day	2 days	3 days	7 day mean		
PM <sub>10</sub> (μg/m <sup>3</sup> ): size of interquartile range 11.8 ΔPEF							
Morning							
Effect size	0.38	-0.24	0.32	-0.12	0.79		
Upper 95% Cl	2.24	1.60	2.55	1.83	6.09		
Lower 95% Cl	-1.41	-2.23	-1.88	-2.12	-4.47		
Afternoon							
Effect size	0.63	-0.12	-0.35	-1.65	-2.23		
Upper 95% CI	2.64	1.94	1.73	0.25	3.69		
Lower 95% Cl	-1.29	-2.12	-2.47	-3.64	-8.11		
Prevalent symptoms							
Cough							
Effect size	0.90	0.93	0.96	0.92	1.06		
Upper 95% Cl	1.02	1.07	1.13	1.07	1.57		
Lower 95% Cl	0.79	0.80	0.83	0.79	0.72		
111							
Effect size	1.08*	1.01	1.07	1.06	1.28*		
Upper 95% Cl	1.17	1.09	1.17	1.15	1.60		
Lower 95% Cl	1.00	0.93	0.98	0.98	1.01		
SOB							
Effect size	1.00	0.99	1.00	0.99	0.93		
Upper 95% Cl	1.12	1.08	1.12	1.08	1.22		
Lower 95% Cl	0.91	0.90	0.90	0.89	0.71		
Wake							
Effect size	0.99	1.02	1.00	0.96	1.02		
Upper 95% Cl	1.09	1.13	1.12	1.07	1.33		
Lower 95% Cl	0.90	0.93	0.90	0.88	0.78		
Wheeze							
Effect size	0.93	0.87*	0.87*	0.98	0.91		
Upper 95% CI	1.05	0.96	0.99	1.12	1.28		
Lower 95% Cl	0.83	0.78	0.77	0.87	0.65		

	Lag						
Pollutant	0	1 day	2 days	3 days	7 day mean		
<sup>2</sup> M <sub>2.5</sub> (μg/m <sup>3</sup> ): size of interquartile range 12.3							
\PEF							
Morning							
Effect size	0.80	0.62	-0.86	-2.47	-4.07		
Upper 95% Cl	3.67	3.54	2.47	0.36	2.42		
Lower 95% Cl	-1.97	-2.22	-4.32	-5.30	-10.60		
Atternoon	0.05	0.00	1 (0	0.45*	1.00		
Effect size	0.95	-0.99	-1.60	-3.45^	1.00		
Upper 95% CI	4.23	2.72	2.01	-0.25	13.30		
Lower 95% CI	-2.22	-4.09	-5.18	-0.53	-11.47		
Prevalent symptoms							
Cough							
Effect size	0.98	0.95	1.02	1.01	1.31		
Upper 95% Cl	1.18	1.17	1.24	1.23	2.09		
Lower 95% Cl	0.80	0.77	0.83	0.83	0.82		
Effect size	1.17*	1.07	1.16*	1.01	1.57*		
Upper 95% Cl	1.32	1.23	1.35	1.16	2.13		
Lower 95% Cl	1.05	0.95	1.01	0.90	1.15		
OB							
Effect size	1.07	0.98	0.96	0.91	0.82		
Upper 95% CI	1.24	1.13	1.13	1.07	1.18		
Lower 95% Cl	0.94	0.84	0.82	0.79	0.58		
Vake							
Effect size	1.10	1.05	0.98	0.94	0.93		
Upper 95% CI	1.26	1.22	1.13	1.09	1.32		
Lower 95% Cl	0.96	0.90	0.83	0.81	0.66		
/heeze							
Effect size	0.98	0.90	1.00	1.13	1.02		
Upper 95% CI	1.16	1.05	1.20	1.35	1.57		
Lower 95% CI	0.83	0.75	0.83	0.95	0.68		
IO₂ (ppb): size of interquartile range 13.6 PEF Aorning Effect size Upper 95% CI	-0.81 2.01	0.08 2.95	-0.54 2.60	-1.49 1.63	-6.10 2.53		
Lower 95% Cl	-3.66	-2.71	-3.93	-4.47	-14.91		
fternoon							
Effect size	0.26	-1.76	-0.27	-1.63	1.80		
Upper 95% CI	3.31	0.96	2.82	1.41	13.20		
Lower 95% Cl	-2.71	-4.61	-3.39	-4.61	-9.49		
evalent symptoms							
Effect size	0.85	1.00	1 1 2	1.00	1 41		
Upper 9.5% Cl	1.05	1.00	1.40	1.35	2.67		
Lower 95% Cl	0.68	0.79	0.90	0.89	0.76		
	0.00	0.77	0.70	0.07	0.70		
Effect size	1 12	0.96	1 04	1.00	1 17		
Upper 95% Cl	1.26	1.08	1 20	115	1.80		
Lower 95% Cl	0.99	0.85	0.92	0.89	0.78		
OB	0.77	0.00	5.72	5.67	5.7 0		
Effect size	1.05	0.95	0.95	0.92	0.56*		
Upper 95% CI	1.21	1.09	1.09	1.08	0.91		
Lower 95% Cl	0.91	0.83	0.80	0.78	0.35		
/ake	0.7 1	0.00	0.00	0.7 0	0.00		
Effect size	1.08	1.00	0.96	0.92	0.66		
Upper 95% CI	1.24	1,15	1.09	1.07	1.05		
Lower 95% Cl	0.95	0.87	0.83	0.80	0.42		
'heeze	2.70	0.07	5.00	5.00	52		
Effect size	0.85	0.91	0.85	1.08	0.83		
Upper 95% Cl	1.01	1.07	1.01	1.31	1.50		
lower 95% Cl	0.73	0.77	0.72	0.91	0.46		
	0.75	0.77	0.72	0.71	0.40		
zone (ppb): size of interquartile range 21.5 'EF							
lorning							
Effect size	3.10	1.23	2.28	4.00	17.53*		
Upper 95% CI	8.26	6.11	7.42	8.91	28.52		
Lower 95% CI	-1.94	-3.66	-2.80	-0.86	6.56		
ternoon							
Effect size	-0.43	1.25	1.85	3.23	0.28		
Upper 95% CI	4.41	5.55	6.28	7.74	9.79		
Lower 95% Cl	-5.38	-3.01	-2.37	-1.29	-9.03		

	Lag	Lag						
Pollutant	0	1 day	2 days	3 days	7 day mea			
evalent symptoms								
bugh								
Effect size	1.44*	1.12	1.16	1.02	0.88			
Upper 95% Cl	2.05	1.59	1.62	1.40	1.81			
Lower 95% Cl	1.00	0.77	0.84	0.74	0.42			
Effect size	0.91	1.32*	1.04	1.02	1.53			
Upper 95% CI	1.12	1.62	1.29	1.27	2.53			
Lower 95% CI	0.74	1.09	0.84	0.84	0.94			
DB								
Effect size	1.00	1.21	1.27	1.24	2.79*			
Upper 95% Cl	1.27	1.53	1.62	1.59	4.95			
lower 95% Cl	0.77	0.94	0.98	0.96	1.56			
ake	0,	0.7.1	0.70	0.70				
Effect size	1.00	1.09	1.24	1.24	1 97*			
Linner 95% Cl	1.00	1.37	1.24	1.24	3.50			
	0.70	0.94	0.04	0.00	1.10			
	0.79	0.00	0.90	0.98	1.12			
	1 40*	1.25	1.07*	0.02	1.50			
	1.40^	1.35	1.3/^	0.83	1.59			
	1.84	1.//	1.84	1.09	3.31			
ower 95% Cl	1.06	1.00	1.02	0.61	0.//			
2 (ppb): size of interquartile range 4.0	)							
orning								
Effect size	-0.60	0.08	-0.16	0.27	-115			
Inner 95% Cl	1 32	1.86	1.64	2 00	3.74			
ower 95% Cl	_2 51	-1.67	_1.04	_1 51	-6.09			
ernoon	-2.51	1.07	1.77	1.51	0.07			
Effect size	0.32	0.88	0.76	0.20	1 10			
Incor size	2.04	1 10	1.25	1.62	-1.17			
ower 95% Cl	_2.04	-2.87	_2 79	-2.07	-8.88			
	2.7 1	2.07	2.77	2.07	0.00			
evalent symptoms								
lugh								
attect size	0.92	1.00	1.05	1.03	0.81			
Upper 95% Cl	1.05	1.15	1.19	1.17	1.15			
Lower 95% Cl	0.81	0.87	0.92	0.90	0.58			
Effect size	1.09*	1.03	1.07	0.98	1.32*			
Jpper 95% Cl	1.18	1.11	1.17	1.06	1.64			
ower 95% Cl	1.01	0.95	0.99	0.90	1.06			
B								
Effect size	1.02	1.00	0.98	0.97	0.81			
Jpper 95% Cl	1.13	1.09	1.08	1.07	1.03			
ower 95% Cl	0.93	0.90	0.89	0.89	0.63			
ike								
ffect size	1.00	1.05	1.06	0.94	0.87			
Jpper 95% Cl	1.10	1.15	1.16	1.04	1.10			
ower 95% Cl	0.91	0.96	0.96	0.87	0.68			
heeze	0.71	0.70	0.70	0.07	0.00			
-ffect size	0.96	0.96	0.95	1.01	0.91			
Inner 95% Cl	1.07	1.07	1.06	1 1 3	1 22			
	1.0/	0.07	0.05	0.00	0.40			

and HCl) and other pollutants. A similar pattern of association was noted in the summer, although the values of *r* were generally lower. However, in the summer, levels of HNO<sub>3</sub> were correlated with those for the particulate mass measures (PM<sub>10</sub>, r=0.77; PM<sub>2.5</sub>, r=0.81) and NO<sub>2</sub> (r=0.65).

Particulate levels were similar between the two locations, particularly in the case of  $PM_{25}$ , consistent with its long atmospheric lifetime (winter  $PM_{25}$ , r=0.80). Measured components of the particulate matter ( $SO_4^{2-}$ ,  $NO_3^-$ ,  $NH_4^+$ ,  $CI^-$ ) were reasonably correlated between the two sites (r=0.63-0.93), while the gaseous acid and anions (HCl, HNO<sub>3</sub>, NH<sub>3</sub>) showed a lower degree of correlation (r=0.12-0.73).

#### Identification of regression models

For  $\Delta PEF$ , square root trend terms were included as this improved model fit for the Birmingham panel. Similarly,

quadratic trend terms were included in symptom models as model fit was generally improved for both panels. Minimum temperature was included in all models, although variations were seen in the lag chosen. The closest association between wintertime  $\Delta PEF$ , prevalent symptoms, and minimum temperature was seen for the 7 day prior mean. In contrast, incident symptoms were most clearly associated with the same day's minimum temperature (except Birmingham illness and wheeze models which included the 7 day prior mean). The majority of summer outcomes were most closely associated with the same or previous day's minimum temperature, except incident and prevalent illness for which models also included the 7 day mean. Additionally, inclusion of relative humidity improved model fit for winter  $\Delta PEF$  and prevalent symptoms, but not other meteorological variables or summer pollen count.

**Table 4**Results of the final models for the entire panel during the winter period: estimated effect size (change in  $\Delta PEF$ (I/min) or symptom odds per pollutant rise across interquartile range) and 95% confidence intervals (CI) for mass<br/>concentration of particulates and gaseous pollutants

Pollutant         0         1 day         2 days         3 days         7 day mean           HNO, (ug/m)': size of interquartile range 0.4 APEF	
HNO <sub>2</sub> [µg/m <sup>2</sup> ]: size of interquartile range 0.4         APEF         Morning         Effect size       -1.16       -1.07       -0.21       -1.03       -1.78         Upper 95% Cl       0.36       0.37       1.35       0.44       1.89         Lower 95% Cl       -2.67       -2.50       -1.77       -2.51       -5.45         Afternoon       -0.35       0.87       0.41       -0.87       -0.27         Upper 95% Cl       1.24       2.31       1.96       0.62       6.34         Lower 95% Cl       -1.94       -0.57       -1.13       -2.36       -6.87         Prevalent symptoms       -0.93       0.95       0.94       0.81       0.84         III       0.97       0.96       1.01       1.02       1.09         Upper 95% Cl       1.04       1.03       1.07       1.09       1.32         Upper 95% Cl       0.97       0.96       1.01       1.02       1.09         Upper 95% Cl       0.04       0.90       0.94       0.95       0.90         SOB       Effect size       0.97       0.96       1.01       1.02       1.09         Upper 95% Cl       0.90       0.90 <th></th>	
APEF         Morning         Effect size       -1.16       -1.07       -0.21       -1.03       -1.78         Upper 95% C1       0.36       0.37       1.35       0.44       1.89         Lower 95% C1       -2.67       -2.50       -1.77       -2.51       -5.45         Afternoon       -       -       -       -       -       -         Effect size       -0.35       0.87       0.41       -0.87       -0.27         Upper 95% C1       1.24       2.31       1.96       0.62       6.34         Lower 95% C1       -1.94       -0.57       -1.13       -2.36       -6.87         Prevalent symptoms       -       -       -1.04       1.05       1.05       0.90*       1.14         Upper 95% C1       1.16       1.16       1.16       1.00       1.54         Upper 95% C1       0.93       0.95       0.94       0.81       0.84         III       Effect size       0.97       0.96       1.01       1.02       1.09         Upper 95% C1       0.91       0.90       0.94       0.95       0.90       SOB         Effect size       0.97       0.9*       0.91* <td></td>	
Motining Effect size       -1.16       -1.07       -0.21       -1.03       -1.78         Upper 95% CI       0.36       0.37       1.35       0.44       1.89         Lower 95% CI       -2.67       -2.50       -1.77       -2.51       -5.45         Afternon	
Upper 95% CI       0.36       0.37       1.33       0.44       1.89         Lower 95% CI       -2.67       -2.50       -1.77       -2.51       -5.45         Afternoon       Effect size       -0.35       0.87       0.41       -0.87       -0.27         Upper 95% CI       1.24       2.31       1.96       0.62       6.34         Lower 95% CI       -1.94       -0.57       -1.13       -2.36       -6.87         Prevalent symptoms       Cough       Effect size       1.04       1.05       1.05       0.90*       1.14         Upper 95% CI       1.16       1.16       1.16       1.00       1.54         Upper 95% CI       0.93       0.95       0.94       0.81       0.84         III       Effect size       0.97       0.96       1.01       1.02       1.09         Upper 95% CI       0.91       0.90       0.94       0.95       0.90         Lower 95% CI       0.91       0.90       0.94       0.95       0.90         SOB       Effect size       0.97       0.97       0.98       1.08       0.99         Lower 95% CI       0.90       0.83       0.84       0.92       0.63	
Lower 95% CI -2.67 -2.50 -1.77 -2.51 -5.45 Afternoon Effect size -0.35 0.87 0.41 -0.87 -0.27 Upper 95% CI -1.24 2.31 1.96 0.62 6.34 Lower 95% CI -1.94 -0.57 -1.13 -2.36 -6.87 Prevalent symptoms Cough Effect size 1.04 1.05 1.05 0.90* 1.14 Upper 95% CI 0.16 1.16 1.16 1.00 1.54 Lower 95% CI 0.93 0.95 0.94 0.81 0.84 III Effect size 0.97 0.96 1.01 1.02 1.09 Upper 95% CI 1.04 1.03 1.07 1.09 1.32 Lower 95% CI 0.91 0.90 0.94 0.95 0.90 SOB Effect size 0.97 0.9* 0.91* 1.00 0.79* Upper 95% CI 1.05 0.97 0.98 1.08 0.99 SOB Effect size 0.97 0.9* 0.91* 1.00 0.79* Upper 95% CI 1.05 0.97 0.98 1.08 0.99 Lower 95% CI 1.05 0.97 0.98 1.08 0.99 Lower 95% CI 1.04 0.97 0.98 1.08 0.99 Lower 95% CI 0.90 0.83 0.84 0.92 0.63 Wake Effect size 0.96 0.90* 0.90* 0.90* 1.02 0.78* Upper 95% CI 1.04 0.97 0.98 1.08 0.99 Lower 95% CI 0.089 0.83 0.84 0.94 0.63 Wake Effect size 1.00 0.97 0.98 1.10 0.96 Lower 95% CI 0.08 0.89* 0.97 0.76* Upper 95% CI 1.00 0.98 0.89 0.83 0.84 0.94 0.63 Wheeze Effect size 1.00 0.98 0.89* 0.97 0.76* Upper 95% CI 1.10 1.07 0.98 1.07 0.99 Lower 95% CI 0.091 0.91 0.89 0.82 0.88 0.58 SO <sub>2</sub> <sup>2</sup> (µg/m <sup>3</sup> ): size of interquantile range 4.8 APEF	
Afternoon         Effect size       -0.35       0.87       0.41       -0.87       -0.27         Upper 95% CI       1.24       2.31       1.96       0.62       6.34         Lower 95% CI       -1.94       -0.57       -1.13       -2.36       -6.87         Prevalent symptoms       -0.57       -1.13       -2.36       -6.87         Cough       -0.93       0.95       0.94       0.81       0.84         Ill       1.16       1.16       1.00       1.54         Lower 95% CI       0.93       0.95       0.94       0.81       0.84         Ill	
Effect size       -0.35       0.87       0.41       -0.87       -0.27         Upper 95% CI       1.24       2.31       1.96       0.62       6.34         Lower 95% CI       -1.94       -0.57       -1.13       -2.36       -6.87         Prevalent symptoms       -0.57       -1.13       -2.36       -6.87         Cough       -       -       -0.57       -1.13       -2.36       -6.87         Prevalent symptoms       -       -       -0.57       -1.13       -2.36       -6.87         Cough       -       -       -       -0.57       -1.13       -2.36       -6.87         Prevalent symptoms       -       -       -       -       -0.57       -1.13       -2.36       -6.87         Effect size       1.04       1.05       1.05       0.90*       1.14       1.00       1.54         Lower 95% CI       1.04       1.03       1.07       1.09       1.32       1.09         Upper 95% CI       0.91       0.90       0.94       0.95       0.90       SOB       -0.97       0.94       0.91*       1.00       0.79*         Upper 95% CI       0.90       0.83       0.84       0.92	
Upper 95% CI       1.24       2.31       1.96       0.62       6.34         Lower 95% CI       -1.94       -0.57       -1.13       -2.36       -6.87         Prevalent symptoms       Effect size       1.04       1.05       1.05       0.90*       1.14         Upper 95% CI       1.16       1.16       1.16       1.00       1.54         Lower 95% CI       0.93       0.95       0.94       0.81       0.84         III       Effect size       0.97       0.96       1.01       1.02       1.09         Upper 95% CI       1.04       1.03       1.07       1.09       1.32         Uower 95% CI       0.91       0.90       0.94       0.95       0.90         SOB       Effect size       0.97       0.94       0.91*       1.00       0.79*         Upper 95% CI       0.90       0.94       0.95       0.90       SOB       0.90       0.94       0.95       0.90         Effect size       0.97       0.97       0.98       1.08       0.99       0.90       0.94       0.63         Woke       0.90       0.83       0.84       0.92       0.63       0.84       0.92       0.63	
Prevalent symptoms         Cough         Effect size       1.04       1.05       1.16       1.16         Upper 95% CI       1.16       1.16       1.16       1.00       1.54         Lower 95% CI       0.93       0.95       0.94       0.81       0.84         III       Effect size       0.97       0.96       1.01       1.02       1.09         Upper 95% CI       1.04       1.03       1.07       1.09       1.32         Lower 95% CI       0.91       0.90       0.94       0.95       0.90         SOB       Effect size       0.97       0.94       0.95       0.90         SOB       Upper 95% CI       1.05       0.97       0.91*       1.00       0.79*         Upper 95% CI       1.05       0.97       0.98       1.08       0.99         Lower 95% CI       0.90       0.83       0.84       0.92       0.63         Wake       Effect size       0.96       0.90*       1.02       0.78*         Upper 95% CI       1.04       0.97       0.98       1.10       0.96         Lower 95% CI       0.89       0.83       0.84       0.94       0.63	
Prevalent symptoms         Cough         Effect size       1.04       1.05       1.05       0.90*       1.14         Upper 95% CI       1.16       1.16       1.16       1.00       1.54         Lower 95% CI       0.93       0.95       0.94       0.81       0.84         III       Effect size       0.97       0.96       1.01       1.02       1.09         Upper 95% CI       1.04       1.03       1.07       1.09       1.32         Lower 95% CI       0.91       0.90       0.94       0.95       0.90         SOB       Effect size       0.97       0.9*       0.91*       1.00       0.79*         Upper 95% CI       1.05       0.97       0.98       1.08       0.99         Lower 95% CI       0.90       0.83       0.84       0.92       0.63         Wake       Effect size       0.96       0.90*       0.90*       1.02       0.78*         Upper 95% CI       1.04       0.97       0.98       1.10       0.96         Lower 95% CI       0.89       0.83       0.84       0.94       0.63         Wheeze       Effect size       1.00       0.98       0.89* <td></td>	
Effect size       1.04       1.05       1.05       0.90*       1.14         Upper 95% CI       1.16       1.16       1.16       1.00       1.54         Lower 95% CI       0.93       0.95       0.94       0.81       0.84         III       Effect size       0.97       0.96       1.01       1.02       1.09         Upper 95% CI       1.04       1.03       1.07       1.09       1.32         Lower 95% CI       0.91       0.90       0.94       0.95       0.90         SOB       0.91       0.90       0.94       0.95       0.90         SOB       0.97       0.9*       0.91*       1.00       0.79*         Upper 95% CI       0.97       0.9*       0.91*       1.00       0.79*         Upper 95% CI       0.90       0.83       0.84       0.92       0.63         Wake	
Upper 95% CI1.161.161.161.001.54Lower 95% CI0.930.950.940.810.84IIIEffect size0.970.961.011.021.09Upper 95% CI1.041.031.071.091.32Lower 95% CI0.910.900.940.950.90SOB00.970.9*0.91*1.000.79*Upper 95% CI1.050.970.981.080.99Lower 95% CI0.900.830.840.920.63WakeEffect size0.960.90*0.90*1.020.78*Upper 95% CI1.040.970.981.100.96Lower 95% CI0.890.830.840.940.63WakeEffect size0.960.90*0.980.970.76*Upper 95% CI1.000.980.89*0.970.76*Upper 95% CI0.910.890.820.880.58SO $_2^{2^2}$ (ug/m³): size of interquartile range 4.8APEF	
Lower 95% Cl         0.93         0.95         0.94         0.81         0.84           III         Effect size         0.97         0.96         1.01         1.02         1.09           Upper 95% Cl         1.04         1.03         1.07         1.09         1.32           Lower 95% Cl         0.91         0.90         0.94         0.95         0.90           SOB          0.97         0.9*         0.91*         1.00         0.79*           Upper 95% Cl         0.97         0.9*         0.91*         1.00         0.79*           Upper 95% Cl         0.90         0.83         0.84         0.92         0.63           Wake           0.90         0.83         0.84         0.92         0.63           Wake           1.04         0.97         0.90*         1.02         0.78*           Upper 95% Cl         0.89         0.83         0.84         0.94         0.63           Wheeze           0.97         0.98         1.10         0.63           Effect size         1.00         0.98         0.89*         0.97         0.76*           Upper 95% Cl <td></td>	
III         Effect size       0.97       0.96       1.01       1.02       1.09         Upper 95% CI       1.04       1.03       1.07       1.09       1.32         Lower 95% CI       0.91       0.90       0.94       0.95       0.90         SOB          0.97       0.94       0.95       0.90         SOB          0.97       0.94       0.91       0.090       0.83         Lower 95% CI       0.90       0.83       0.84       0.92       0.63         Wake	
Lefter size $0.97$ $0.96$ $1.01$ $1.02$ $1.09$ Upper 95% CI $1.04$ $1.03$ $1.07$ $1.09$ $1.32$ Lower 95% CI $0.91$ $0.90$ $0.94$ $0.95$ $0.90$ SOBEffect size $0.97$ $0.9^*$ $0.91^*$ $1.00$ $0.79^*$ Upper 95% CI $1.05$ $0.97$ $0.98$ $1.08$ $0.99$ Lower 95% CI $0.90$ $0.83$ $0.84$ $0.92$ $0.63$ WakeEffect size $0.96$ $0.90^*$ $0.90^*$ $1.02$ $0.78^*$ Upper 95% CI $1.04$ $0.97$ $0.98$ $1.10$ $0.96$ Lower 95% CI $0.89$ $0.83$ $0.84$ $0.94$ $0.63$ WheezeEffect size $1.00$ $0.98$ $0.89^*$ $0.97$ $0.76^*$ Upper 95% CI $1.10$ $1.07$ $0.98$ $1.07$ $0.99$ Lower 95% CI $0.91$ $0.89$ $0.82$ $0.88$ $0.58$ SO $_4^{-2}$ ( $\mu g/m^3$ ): size of interquartile range 4.8 $\Delta PEF$ $\Delta PEF$ $\Delta PEF$	
Lower 95% CI       0.91       0.90       0.94       0.95       0.90         SOB       Effect size       0.97       0.9*       0.91*       1.00       0.79*         Upper 95% CI       1.05       0.97       0.98       1.08       0.99         Lower 95% CI       0.90       0.83       0.84       0.92       0.63         Wake       Effect size       0.96       0.97       0.98       1.10       0.96         Lower 95% CI       0.90       0.83       0.84       0.92       0.63         Wake       Effect size       0.96       0.90*       0.90*       1.02       0.78*         Upper 95% CI       1.04       0.97       0.98       1.10       0.96         Lower 95% CI       0.89       0.83       0.84       0.94       0.63         Wheeze       Effect size       1.00       0.98       0.89*       0.97       0.76*         Upper 95% CI       0.91       0.89       0.82       0.88       0.58         SO <sub>4</sub> <sup>2-</sup> (µg/m <sup>3</sup> ): size of interquartile range 4.8       APEF       SO       SO       SO       SO	
SOB         Effect size         0.97         0.9*         0.91*         1.00         0.79*           Upper 95% CI         1.05         0.97         0.98         1.08         0.99           Lower 95% CI         0.90         0.83         0.84         0.92         0.63           Wake         Effect size         0.96         0.90*         0.90*         1.02         0.78*           Upper 95% CI         1.04         0.97         0.98         1.10         0.96           Lower 95% CI         0.89         0.83         0.84         0.94         0.63           Wheeze         Effect size         1.00         0.98         0.89*         0.97         0.76*           Upper 95% CI         0.89         0.83         0.84*         0.94         0.63           Wheeze         Into         0.98         0.89*         0.97         0.76*           Upper 95% CI         0.91         0.89         0.82         0.88         0.58           SO <sub>4</sub> <sup>2-</sup> (µg/m <sup>3</sup> ): size of interquartile range 4.8         APEF         Interview         Int	
Effect size       0.97       0.9*       0.91*       1.00       0.79*         Upper 95% CI       1.05       0.97       0.98       1.08       0.99         Lower 95% CI       0.90       0.83       0.84       0.92       0.63         Wake           0.97*       0.98*       1.02       0.78*         Upper 95% CI       1.04       0.97       0.98*       1.10       0.96       0.94*       0.63         Wake         0.90*       0.90*       1.02       0.78*         Upper 95% CI       1.04       0.97       0.98*       1.10       0.96         Lower 95% CI       0.89*       0.83       0.84       0.94       0.63         Wheeze            0.97*       0.76*         Upper 95% CI       1.10       1.07       0.98       1.07       0.99        0.58         SO <sub>4</sub> <sup>2</sup> - (µg/m <sup>3</sup> ): size of interquartile range 4.8                 Lower 95%           0.89       0.82       0.88       0.58	
Upper 95% CI       1.05       0.97       0.98       1.08       0.99         Lower 95% CI       0.90       0.83       0.84       0.92       0.63         Wake       Effect size       0.96       0.90*       0.90*       1.02       0.78*         Upper 95% CI       1.04       0.97       0.98       1.10       0.96         Lower 95% CI       0.89       0.83       0.84       0.94       0.63         Wheeze       1.00       0.98       0.89*       0.97       0.76*         Upper 95% CI       1.10       1.07       0.98       1.07       0.99         Lower 95% CI       0.91       0.89       0.82       0.88       0.58         SO <sub>4</sub> <sup>2-</sup> (µg/m <sup>3</sup> ): size of interquartile range 4.8         APEF	
Lower 95% CI       0.90       0.83       0.84       0.92       0.63         Wake       Effect size       0.96       0.90*       0.90*       1.02       0.78*         Upper 95% CI       1.04       0.97       0.98       1.10       0.96         Lower 95% CI       0.89       0.83       0.84       0.94       0.63         Wheeze       Effect size       1.00       0.98       0.89*       0.97       0.76*         Upper 95% CI       1.10       1.07       0.98       1.07       0.99         Lower 95% CI       0.91       0.89       0.82       0.88       0.58         SO <sub>4</sub> <sup>2</sup> - (µg/m <sup>3</sup> ): size of interquartile range 4.8       ΔPEF       Vert       Vert       Vert	
Effect size       0.96       0.90*       0.90*       1.02       0.78*         Upper 95% CI       1.04       0.97       0.98       1.10       0.96         Lower 95% CI       0.89       0.83       0.84       0.94       0.63         Wheeze       Effect size       1.00       0.98       0.89*       0.97       0.76*         Upper 95% CI       1.10       1.07       0.98       1.07       0.99         Lower 95% CI       0.91       0.89       0.82       0.88       0.58         SO <sub>4</sub> <sup>2</sup> - (µg/m <sup>3</sup> ): size of interquartile range 4.8       ΔPEF       4.8       4.8	
Upper 95% CI         1.04         0.97         0.98         1.10         0.96           Lower 95% CI         0.89         0.83         0.84         0.94         0.63           Wheeze         Effect size         1.00         0.98         0.89*         0.97         0.76*           Upper 95% CI         1.10         1.07         0.98         1.07         0.99           Lower 95% CI         0.91         0.89         0.82         0.88         0.58           SO <sub>4</sub> <sup>2-</sup> (µg/m <sup>3</sup> ): size of interquartile range 4.8         APEF         Interview         Interview         Interview	
Lower 95% Cl         0.89         0.83         0.84         0.94         0.63           Wheeze         Effect size         1.00         0.98         0.89*         0.97         0.76*           Upper 95% Cl         1.10         1.07         0.98         1.07         0.99           Lower 95% Cl         0.91         0.89         0.82         0.88         0.58           SO <sub>4</sub> <sup>2</sup> - (µg/m <sup>3</sup> ): size of interquartile range 4.8         ΔPEF         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         0         9         0         8         0         58         1	
Wheeze         Effect size         1.00         0.98         0.89*         0.97         0.76*           Upper 95% CI         1.10         1.07         0.98         1.07         0.99           Lower 95% CI         0.91         0.89         0.82         0.88         0.58           SO <sub>4</sub> <sup>2-</sup> (µg/m <sup>3</sup> ): size of interquartile range 4.8         4         4         4         4         4	
Ettect size       1.00       0.98       0.89*       0.97       0.76*         Upper 95% Cl       1.10       1.07       0.98       1.07       0.99         Lower 95% Cl       0.91       0.89       0.82       0.88       0.58         SO <sub>4</sub> <sup>2-</sup> (µg/m <sup>2</sup> ): size of interquartile range 4.8       APEF       1.10       1.10       1.10       1.10	
Opper 93% C1         1.10         1.07         0.98         1.07         0.99           Lower 95% Cl         0.91         0.89         0.82         0.88         0.58           SO <sub>4</sub> <sup>2-</sup> (µg/m <sup>3</sup> ): size of interquartile range 4.8         APEF         -         -         -	
$SO_4^{-2}$ ( $\mu g/m^3$ ): size of interquartile range 4.8 $\Delta PEF$	
SO <sub>4</sub> <sup>2-</sup> (µg/m <sup>3</sup> ): size of interquartile range 4.8 ΔPEF	
Morning Effect size $-175 - 0.91 - 0.62 - 1.82 - 3.22$	
Upper 95% Cl 0.50 1.62 1.91 0.64 1.58	
Lower 95% Cl -4.00 -3.44 -3.16 -4.27 -8.03	
Afternoon	
Ethect size 0.99 0.79 -1.89 -1.73 -1.96	
Upper 95% CI 5.55 4.00 1.21 1.23 9.42 Lower 95% CI 1.58 -2.42 -4.09 -4.69 -13.35	
Prevalent symptoms	
Effect size 1.01 1.02 0.99 0.86 0.78	
Upper 95% Cl 1.20 1.24 1.20 1.05 1.14	
Lower 95% Cl 0.84 0.85 0.82 0.71 0.53	
Lifect size 1.00 1.15° 1.14° 1.04 1.30*	
Lower 95% Cl 0.96 1.03 1.00 0.92 1.00	
SOB	
Effect size 0.96 0.98 0.94 0.93 0.80	
Upper 95% CI 1.07 1.12 1.07 1.08 1.07	
Unit U.80 U.80 U.82 U.81 U.59 Wake	
Effect size 0.97 1.01 1.00 0.93 0.79	
Upper 95% Cl 1.08 1.15 1.14 1.07 1.05	
Lower 95% Cl 0.87 0.89 0.88 0.82 0.59	
Wheeze         1.00         0.04         0.09         1.10         0.02	
Liner 95% Cl 115 113 104 132 120	
Lower 95% Cl 0.87 0.82 0.75 0.95 0.58	
$NO_3^{-1}$ [µg/m <sup>2</sup> ]: size of interquartile range 6./ APEF	
Morning	
Effect size -2.08* -0.64 0.71 -1.38 -0.92	
Upper 95% Cl -0.15 1.59 3.11 0.84 3.47	
Lower 95% Cl -4.02 -2.87 -1.69 -3.61 -5.32	
Atternoon Effect size 0.24 _0.72 1.37 2.54 0.21	
Upper 95% Cl 2.38 2.43 2.38 0.66 8 11	
Lower 95% Cl -1.89 -3.87 -5.11 -5.74 -7.67	

	Lag						
Pollutant	0	1 day	2 days	3 days	7 day mean		
Prevalent symptoms							
Cough							
Effect size	0.92	0.91	0.99	0.87	0.71*		
Upper 95% Cl	1.07	1.07	1.17	1.03	0.97		
Lower 95% CI	0.80	0.77	0.83	0.73	0.52		
11							
Effect size	1.05	1.11*	1.13*	1.13*	1.13		
Upper 95% Cl	1.14	1.22	1.26	1.26	1.38		
Lower 95% CI	0.97	1.01	1.01	1.01	0.92		
SOB							
Effect size	0.99	1.01	0.93	0.98	0.85		
Upper 95% Cl	1.10	1.13	1.05	1.13	1.08		
Lower 95% CI	0.90	0.90	0.82	0.86	0.67		
Wake							
Effect size	0.98	1.05	0.99	0.99	0.84		
Upper 95% Cl	1.08	1.16	1.12	1.12	1.05		
Lower 95% CI	0.89	0.94	0.88	0.87	0.67		
Wheeze							
Effect size	0.98	1.00	0.89	1.11	0.80		
Upper 95% Cl	1.10	1.14	1.03	1.30	1.07		
Lower 95% CI	0.87	0.87	0.77	0.95	0.61		

**Table 5** Results of the final models for the entire panel during the summer period: estimated effect size (change in ΔPEF (l/min) or symptom odds per pollutant rise across interquartile range) and 95% confidence intervals (CI) for mass concentration of particulates and gaseous pollutants

	Lag						
Pollutant	0	1 day	2 days	3 days	7 day mean		
PM <sub>10</sub> (μg/m <sup>3</sup> ): size of interquartile range 9.0							
APEF							
Morning	1.57	0.10	0.00	0.0/*	1.0.4		
Effect size	-1.56	-0.10	0.90	3.36^	1.24		
Upper 95% CI	0.68	2.33	3.30	5.61	6.29		
Lower 95% CI	-3.81	-2.53	-1.30	1.12	-3.82		
	1.00	1 54	0.15	0.05	0.95		
Effect size	-1.28	-1.50	-0.15	-0.05	-0.85		
Upper 95% Cl	0.07	0.41	1.85	2.03	5.40		
Lower 93% CI	-3.23	-3.54	-2.15	-2.13	-5.09		
Prevalent symptoms							
Cough							
Effect size	1.13*	1.04	0.96	0.89*	0.86		
Upper 95% Cl	1.23	1.14	1.05	0.96	1.07		
Lower 95% Cl	1.05	0.95	0.88	0.82	0.71		
Effect size	1.01	0.97	0.96	0.97	0.96		
Upper 95% CI	1.13	1.11	1.08	1.10	1.41		
Lower 95% Cl	0.89	0.85	0.84	0.86	0.65		
SOB							
Effect size	0.98	1.06	1.00	0.96	1.27		
Upper 95% Cl	1.14	1.25	1.16	1.11	1.78		
Lower 95% Cl	0.85	0.91	0.86	0.82	0.91		
Wake							
Effect size	0.92	0.75*	0.91	0.92	1.24		
Upper 95% Cl	1.10	0.91	1.10	1.08	2.05		
Lower 95% Cl	0.77	0.62	0.74	0.78	0.75		
Wheeze							
Effect size	0.96	0.90	0.88	0.82*	0.95		
Upper 95% Cl	1.14	1.06	1.05	0.96	1.53		
Lower 95% CI	0.83	0.76	0.74	0.69	0.59		
PM <sub>2.5</sub> (µg/m <sup>3</sup> ): size of interquartile range 6.3 APEF							
Morning							
Effect size	-1.49	0.21	2.5*	3.41*	3.90		
Upper 95% Cl	0.67	2.55	4.72	5.44	10.33		
lower 95% Cl	-3.65	-2.12	0.28	1 40	-2.53		
Afternoon	0.00	2.12	0.20	1.40	2.00		
Effect size	-0.49	-0.78	0.57	0.16	-0.08		
Upper 95% Cl	1 45	1.16	2.49	2 17	5.27		
lower 95% Cl	-2 43	-2.72	-1.35	-1.85	-5.43		
	2.40	L./ L	1.00	1.00	0.40		

	Lag						
ollutant	0	1 day	2 days	3 days	7 day mean		
valent symptoms							
	1.10*	1.04	0.04	0.00*	0.01		
Litrect size	1.13*	1.04	0.94	0.89*	1.06		
lower 95% Cl	1.22	0.04	0.87	0.90	0.62		
	1.04	0.74	0.87	0.02	0.02		
Effect size	1.02	1.00	0.96	0.97	0.68		
Jpper 95% Cl	1.13	1.13	1.07	1.09	1.13		
ower 95% Cl	0.91	0.89	0.85	0.86	0.41		
В							
ffect size	1.04	1.08	0.97	0.93	1.16		
Jpper 95% Cl	1.20	1.25	1.13	1.08	1.77		
ower 95% Cl	0.90	0.93	0.84	0.81	0.76		
	0.00	0.01+	0.01	0.07	1.0.4		
	0.93	0.81*	0.91	0.97	1.04		
pper 95% Cl	0.79	0.98	0.77	0.83	0.57		
	0.76	0.07	0.77	0.05	0.57		
ect size	1.02	0.98	0.87	0.85*	0.96		
oper 95% Cl	1.19	1,16	1.02	0.99	1.81		
wer 95% Cl	0.88	0.84	0.74	0.72	0.51		
<sub>2</sub> (ppb): size of interquartile range 7.0							
f i i i i i i i i i i i i i i i i i i i							
ning							
tect size	0.46	1.20	1.87*	1.54	0.91		
pper 95% Cl	2.33	3.09	3.68	3.33	4.73		
wer 95% Cl	-1.42	-0.70	0.06	-0.26	-2.90		
noon	0.77	0.47	0.02	0.09	1.01		
ect size	-0.77	-0.0/	-0.02	1.73	1.21		
ver 95% Cl	_2 31	_2 20	_1.55	_1.75	4.33		
	-2.51	-2.20	-1.50	-1.55	-1.71		
ent symptoms							
h							
ect size	1.09*	0.98	0.93*	0.94	0.87		
per 95% CI	1.17	1.06	1.00	1.01	1.04		
/er 95% Cl	1.01	0.91	0.87	0.87	0.74		
ect size	1.01	0.99	0.95	0.96	0.78		
per 95% Cl	1.12	1.10	1.07	1.08	1.09		
wer 95% Cl	0.91	0.89	0.84	0.85	0.56		
	1.1.1	1.0.4	1.00	0.00	1.1.4		
cr size	1.11	1.04	1.02	0.99	1.14		
er 95% Cl	0.00	1.18	1.15	1.11	1.40		
31 75% CI	0.99	0.93	0.91	0.89	0.89		
, act size	0.99	0.87	0.98	0.96	0.99		
oper 95% CI	1,17	1.01	1.13	1.11	1.42		
wer 95% Cl	0.83	0.74	0.85	0.84	0.70		
eze							
fect size	0.97	0.91	0.89	0.89	0.93		
oper 95% Cl	1.10	1.03	1.04	1.04	1.39		
ver 95% Cl	0.85	0.80	0.77	0.76	0.62		
(ppb): size of interquartile range 10.2							
ing							
ny act size	_1.61	_2 30	_3 /2*	_2 51	_5 66*		
per 9.5% Cl	1.01	0.34	_0.72	0.20	_0.09		
wer 95% Cl	-4.24	-5 11	-6.12	-5.23	-11 21		
oon	/	0	02	0.20			
ect size	-0.13	-2.32	-0.12	2.02	-0.14		
per 95% Cl	2.40	0.04	2.40	4.38	5.04		
/er 95% Cl	-2.66	-4.68	-2.64	-0.34	-5.34		
ent symptoms							
h 	0.00	1.07	1.05	1.00	0.05		
ct size	0.99	1.07	1.05	1.02	0.95		
ber 95% CI	1.08	1.18	1.16	1.13	1.19		
er 95% CI	0.89	0.97	0.96	0.93	0.76		
	0.01	1.00	1 1 1	1 1 1	1 1 4		
	1.05	1.08	1.11	1.11	1.10		
ver 95% Cl	0.70	0.01	0.95	0.96	0.85		
	0.79	0.91	0.95	0.90	0.05		
act size	1.02	1.04	1.07	116	1.35		
er 95% Cl	1.02	1 24	1 27	1.38	1 94		
wer 95% Cl	0.85	0.87	0.91	0.98	0.95		

	Lag						
Pollutant	0	1 day	2 days	3 days	7 day mean		
Wake							
Effect size	0.98	0.98	0.90	0.96	1.18		
Upper 95% Cl	1 19	1 18	1.08	1 18	1.87		
lower 95% Cl	0.81	0.81	0.75	0.79	0.75		
Vheeze	0.01	0.01	0.70	0 /	0.70		
Effect size	0.83*	0.8*	0.83*	0.88	0.88		
Upper 95% Cl	0.00	0.03	1.00	1.06	1 38		
Lower 95% Cl	0.71	0.69	0.70	0.74	0.57		
O <sub>2</sub> (ppb): size of interquartile range 2.2 PEF							
Aorning							
Effect size	0.91	0.29	0.95	2.7*	6.83*		
Upper 95% CI	2.78	2.14	2.82	4.38	12.69		
Lower 95% CI	-0.95	-1.56	-0.92	1.03	0.98		
fternoon							
Effect size	-0.89	-0.02	-0.41	0.02	-2.48		
Upper 95% CI	0.83	1.65	1.24	1.61	2.59		
ower 95% Cl	-2.61	-1.68	-2.05	-1.58	-7.56		
evalent symptoms							
ough							
Effect size	1.08*	1.04	1.02	0.98	0.96		
Upper 95% CI	1.15	1.11	1.09	1.05	1.22		
Lower 95% Cl	1.02	0.97	0.95	0.91	0.75		
Effect size	1.05	1.02	1.00	0.94	1.07		
Upper 95% CI	1.14	1.12	1.10	1.02	1.47		
Lower 95% CI	0.96	0.94	0.92	0.86	0.78		
OB							
Effect size	0.98	1.00	1.02	0.92	0.92		
Upper 95% Cl	1.10	1.13	1.16	1.05	1.36		
lower 9.5% Cl	0.87	0.89	0.90	0.81	0.62		
/ake	0.07	0.07	0.70	0.01	0.02		
Effect size	1.00	1.02	0.95	0.94	1 13		
Linear 92% Cl	1.00	1.02	1.08	1.06	1.88		
Lower 95% CL	0.87	0.80	0.84	0.83	0.67		
lower 7570 CI	0.07	0.07	0.04	0.05	0.07		
Effect size	1.05	1.00	1.06	0.94	0.90		
Linear 95% Cl	1.05	1.00	1.00	1.07	1.22		
	0.02	1.13	0.04	0.02	1.33		

**Table 6** Results of the final models for the entire panel during the summer period: estimated effect size (change in △PEF (l/min) or symptom odds per pollutant rise across interquartile range) and 95% confidence intervals (CI) for mass concentration of particulates and gaseous pollutants

	Lag					
Pollutant	0	1 day	2 days	3 days	7 day mean	
HNO <sub>3</sub> ( $\mu$ g/m <sup>3</sup> ): size of interquartile range 1.3 $\Delta$ PEF						
Morning						
Effect size	-1.09	0.53	0.72	2.26*	-0.59	
Upper 95% CI	1.07	2.81	3.06	4.43	6.14	
Lower 95% CI	-3.26	-1.74	-1.62	0.08	-7.31	
Afternoon						
Effect size	-0.08	-0.72	0.36	-1.92	-4.67	
Upper 95% Cl	1.97	1.40	2.49	0.17	0.96	
Lower 95% CI	-2.14	-2.84	-1.77	-4.01	-10.29	
Prevalent symptoms						
Cough						
Effect size	1.09*	1.01	0.94	0.89*	0.66*	
Upper 95% CI	1.19	1.11	1.03	0.97	0.88	
Lower 95% CI	1.00	0.92	0.86	0.82	0.49	
11						
Effect size	0.92	0.98	0.95	1.04	0.79	
Upper 95% Cl	1.04	1.12	1.08	1.18	1.34	
Lower 95% Cl	0.83	0.86	0.83	0.92	0.46	

# Table 6 continued

	Lag					
Pollutant	0	1 day	2 days	3 days	7 day mean	
SOB Effect size	1 04	1.01	0.99	0.95	1.02	
Upper 95% Cl	1.21	1.18	1.15	1.10	1.61	
Lower 95% Cl Wake	0.90	0.86	0.85	0.82	0.65	
Effect size	0.83*	0.76*	0.94	0.89	0.93	
Lower 95% Cl	0.69	0.62	0.78	0.75	0.50	
Wheeze Effort size	0.03	0.87	0.87	0.7*	0.71	
Upper 95% CI	1.09	1.02	1.04	0.82	1.20	
Lower 95% Cl	0.80	0.74	0.73	0.60	0.43	
δO <sub>4<sup>2-</sup></sub> (μg/m <sup>3</sup> ): size of interquartile range 3.1						
Aorning						
Effect size Upper 95% Cl	-0.72 1.82	-1.69 0.90	1.35 3.97	3.38* 5.72	2.98 10.13	
Lower 95% Cl	-3.27	-4.28	-1.27	1.03	-4.17	
Atternoon Effect size	-0.32	0.84	-0.08	-0.25	-2.20	
Upper 95% CI	2.17	3.30	2.44	2.19	5.12	
Lower 93% CI	-2.81	-1.63	-2.61	-2.69	-9.51	
Prevalent symptoms Couch						
Effect size	1.08	1.03	0.97	0.9*	0.73*	
Upper 95% CI Lower 95% CI	0.98	0.93	0.88	0.99	0.97	
[	0.00	0.07	1.01	0.05	0.70	
Upper 95% CI	1.11	1.12	1.16	1.09	1.12	
Lower 95% CI	0.86	0.84	0.88	0.84	0.46	
Effect size	0.95	1.07	1.04	0.94	0.58	
Upper 95% Cl Lower 95% Cl	1.14 0.80	1.28 0.89	1.24 0.87	1.12 0.80	1.04 0.33	
Vake	0.05	0.01*	0.00	0.07	0.77	
Upper 95% CI	1.16	0.81*	1.13	1.05	1.48	
Lower 95% CI	0.78	0.67	0.76	0.72	0.41	
Effect size	0.97	1.09	1.00	0.81*	1.30	
Upper 95% Cl Lower 95% Cl	1.17 0.80	1.32 0.89	1.22 0.82	0.97 0.69	2.50 0.68	
PEF						
Aorning Effect size	-0.80	0.68	1 42	2 51*	1.74	
Upper 95% Cl	1.15	2.67	3.58	4.59	6.13	
Lower 95% Cl Afternoon	-2.74	-1.31	-0.73	0.48	-2.66	
Effect size	-0.72	-0.59	-0.33	0.66	0.47	
Lower 95% Cl	-2.47	-2.36	-2.11	-1.26	-3.36	
revalent symptoms						
Cough	1.05	1.01	0.05	0.00+	0.01+	
Upper 95% Cl	1.05	1.01	1.03	0.89*	0.81*	
Lower 95% Cl	0.97	0.93	0.88	0.83	0.68	
Effect size	0.97	0.98	0.95	0.94	0.74	
Upper 95% Cl	1.09	1.10	1.06	1.05	1.03	
OB ====================================	0.07	0.07	0.00	0.00	0.04	
Ettect size Upper 95% Cl	1.04 1.18	1.12 1.28	1.04 1.20	0.90 1.03	1.06	
Lower 95% Cl	0.90	0.98	0.90	0.79	0.78	
Vake Effect size	0.94	0.86	0.94	0.92	0.95	
Upper 95% Cl	1.09	1.01	1.11	1.07	1.47	
Vheeze	0.00	0.72	0.79	0.79	0.02	
Effect size	1.01	0.96	0.95	0.87	1.04	
Lower 95% Cl	0.87	0.83	0.82	0.75	0.67	

499

\*p<0.05 (t test) to determine probability that effect size different from zero (PEF) or 1 (symptom odds).

Pollutant	Lag (days)	Subgroup with atopy or history of recent wheezing		Subgroup without atopy or history of wheezing		Difference
		Effect size†	95% CI	Effect size†	95% CI	subgroups
Subgroups ba	sed on atopic st	atus:				
PM <sub>10</sub>	0	-0.088	-0.403 to 0.226	0.086	-0.285 to 0.456	
	1	-0.105	-0.407 to 0.198	0.008	-0.363 to 0.379	
	2	0.118	-0.220 to 0.456	-0.014	-0.439 to 0.412	
	3	-0.034	-0.363 to 0.295	-0.005	-0.399 to 0.388	
PM <sub>2.5</sub>	0	0.072	0 527 to 0 282	0.126	0 412 to 0 666	
	0	-0.072	-0.327 10 0.383	0.120	-0.413 10 0.000	
		-0.271	-0.701 to 0.139	0.193	-0.340 to 0.728	
	2	0.12/	-0.354 to 0.608	-0.170	-0.788 to 0.447	
	3	0.055	-0.391 to 0.501	-0.314	-0.846 to 0.216	
HNO3	0	3.506	-4.273 to 11.285	-5.964	-15.195 to 3.266	p<0.05
	1	-0 445	-8 083 to 7 192	-3 866	-12 741 to 5 010	
	2	-7.616*	-14 989 to -0 242	2 588	-6 644 to 11 819	n < 0.05
	2	3 2 4 0	4 568 to 11 049	5 381	14 408 to 2 720	P20.00
	3	5.240	-4.300 10 11.040	-3.304	-14.470 10 3.7 30	
50 <sub>4</sub> <sup>2-</sup>	0	0.200	-0.755 to 1.156	-0.613	-1.714 to 0.488	
	1	-0.219	-1.318 to 0.881	-0.174	-1.423 to 1.075	
	2	-0.431	-1.526 to 0.664	0.006	-1.243 to 1.253	
	3	1.200*	0.095 to2.305	-1.080	-2.308 to 0.148	p<0.05
NO₃ <sup>−</sup>	0	-0.036	–0.627 to 0.555	-0.434	-1.116 to 0.248	
	1	0.142	-0.573 to 0.857	-0.201	-1.002 to 0.600	
	2	0.000	-0.760 to 0.759	0.154	-0.703 to 1.010	
	3	0.689	-0.061 to 1.439	-0.605	-1.422 to 0.210	p<0.05
Subarouns ba	sed on parental	history of recent y	wheezing:			
PM.	0	0.072	_0.069 to 0.212	0.019	-0.235 to $0.273$	
14(10	1	0.00/2	0.045 to 0.233	0.045	-0.200 + 0.0270	
	2	0.013	0 120 to 0 166	0.000	-0.024100.170	
	2	0.013	-0.13910 0.100	0.031	-0.207 to $0.330$	
	0	-0.044	-0.10710-0.102	-0.005	-0.27 0 10 0.200	
PM <sub>2.5</sub>	0	0.187	-0.008 to 0.382	0.026	-0.341 to 0.395	
	1	-0.006	-0.207 to 0.195	0.068	-0.307 to 0.444	
	2	-0.011	-0.226 to 0.204	-0.099	-0.535 to 0.335	
	3	-0.037	-0.228 to 0.154	-0.252	-0.615 to 0.110	
HNO.	0	1.005	2 115 to 4 124	1 321	10 556 to 1 907	
11 103	1	2 266	5 135 to 0 402	2 082	8 860 to 2 004	
	2	1 0 2 5	4 775 to 1 105	-2.702	-0.007 10 2.704 6 400 to 6 192	
	2	-1.035	-4.775101.105	-0.137	-0.477 10 0.183	
	3	-0.442	-3.300 to 2.481	-3.445	-9.496 to 2.60/	
SO42-	0	0.457*	0.003 to 0.910	-0.622	-1.379 to 0.136	p<0.05
-	1	0.078	-0.503 to 0.660	-0.272	-1.147 to 0.602	
	2	-0.102	-0.656 to 0.452	-0.138	-1 005 to 0 728	
	3	0.002	-0.609  to  0.432	-0.496	-1.359 to 0.367	
	U	0.002	0.007 10 0.010	0.470	1.007 10 0.007	
NO₃⁻	0	0.228	-0.054 to 0.511	-0.482*	-0.952 to -0.012	p<0.05
	1	0.476*	0.060 to 0.892	-0.276	-0.846 to 0.294	p<0.05
	2	0.196	-0.202 to 0.594	0.078	-0.520 to 0.675	
	0	0.093	0.321 to 0.487	0.209	-0.864 to 0.268	

**Table 7** Analysis of subgroups based on atopic status (Birmingham n=27, Sandwell n=23) and parental history of recent wheezing (Birmingham n=23, Sandwell n=16) subgroups. Results are only shown for selected pollutants and morning  $\Delta PEF$  (I/min)

In general, first order autocorrelation terms were adequate to remove autoregressive effects from the model residuals, but winter SOB and summer morning  $\Delta PEF$  required additional higher order terms.

#### Pollutant effects on health outcomes

Statistically significant associations between pollutants and  $\Delta$ PEF or respiratory symptoms were seen in both winter (tables 3 and 4) and summer (tables 5 and 6). However, there were no consistent changes, either adverse or otherwise, in any symptom or lung function index when the total panel was considered. Results for incident symptoms and the acid and anion species HCl, Cl<sup>-</sup>, NH<sub>4</sub><sup>+</sup> and NH<sub>3</sub> are not shown for brevity. No pattern in the nature of the pollutants or the lag of

onal PM<sub>25</sub>. Analysis of subgroups based on atopic status or history of recent wheezing

The results do not indicate that children with atopy or a history of recent wheezing are more susceptible to the short term respiratory health effects of air pollutants. Few statistically significant results were noted and the results are presented for winter morning  $\Delta$ PEF only (table 7). However, no pattern between pollutants, their lags, or apparent direction of measured effect are evident for any of the health outcomes studied, nor is there any apparent consistency between the two locations.

greatest measured effect were noted and, in particular, there

were no consistent responses to ozone or particles as PM<sub>10</sub> or

# DISCUSSION

This study provides little evidence for a relationship between the measured pollutants and daily changes in health outcomes after correction for the confounding effects of weather, trends in the data, and autocorrelation. In particular, there is no suggestion that PM<sub>10</sub>, and that individual acid or anion species were more closely associated with such effects than particulate mass measures. In epidemiological studies involving multiple comparisons it is important not to overemphasise individual "significant" results, but rather to attempt to identify clear consistent patterns. In this study no such consistency in pollutant, lag, or location was noted.

The identification of particulate health effects where aerosol strong acidity is very low<sup>3</sup> has focused attention away from acid species generally, and these compounds have not been regarded as important in the UK since the Clean Air Act. In this study, aerosol strong acidity was virtually undetectable and no relationships with acid or basic species, gas or aerosol, were found, although concentrations were low. Sulphate has been regarded by some authors as a surrogate for the mass concentration of fine particulates<sup>19</sup> and, in situations of high aerosol strong acidity, has been found to be more strongly related to respiratory admissions and some symptoms than PM measures.<sup>9 20</sup> In contrast, low levels of aerosol strong acidity were reported in a wintertime Dutch panel of children which identified small effects of  $PM_{10'}$   $NO_2$ ,  $SO_4^{-2}$ ,  $NO_3^{-}$ , and  $HNO_3$  (but not  $SO_2$ ) on lung function,<sup>10</sup> although only short lags were considered. The effects of  $SO_2$  and  $SO_4^{2-}$  on respiratory symptoms were also reported.

Our findings are consistent with those from the PEACE study in which urban and rural panels of 6-12 year old children with a history of recent night time cough or wheeze were monitored across 14 centres for at least two winter months.7 Measures of fine particulate levels and acid species were omitted from this study and few statistically significant associations were found overall, despite a wide range of pollutant and climatic experiences. The authors identified a number of possibilities for these negative findings. Firstly, overall panel effect estimates could potentially be biased by a subgroup within the panel with a different pattern of response. In the PEACE study children with diagnosed asthma taking respiratory medication showed a positive relationship between PEF and pollutant levels, although bronchodilator use was not related to pollutants.<sup>18</sup> In our study, subgroup analyses revealed no consistent effects of pollutants on PEF or respiratory symptoms in children with a previous history of wheezing or atopy. Other authors report contrasting findings; a study of Dutch adults demonstrated that airway "lability", expressed as PEF variability or bronchial hyperresponsiveness (BHR), predicted susceptibility to pollutant effects<sup>21</sup> and, in Dutch children, "allergy", in addition to BHR, has been implicated in susceptibility to increased PM<sub>10</sub>, NO<sub>2</sub>, and SO<sub>2</sub>.<sup>22</sup> It has been suggested that, in susceptible subjects, pollutants may act as "potentiators", increasing the effects of other factors such as allergens which could influence lung function.<sup>23</sup> However, such a relationship could potentially be reversed by the action of bronchodilating medication so that the inclusion of children with diagnosed asthma in an epidemiological study of air pollutants may obscure any real relationships or lead to the paradoxical result of high pollutant levels associated with better health outcomes. This could occur if those with asthma modify their behaviour on high pollutant days, either by the use of bronchodilating drugs3 or by staying indoors and reducing activity.

Selecting individuals with a history of recent wheezing on the basis of a questionnaire may also result in a heterogeneous group. In contrast to our symptomatic subgroup, selected on the basis of recent wheezing only, most centres in the PEACE study included children with nocturnal cough alone. Such

Unmeasured confounders which vary across a suitable time course-for example, respiratory tract infections-could also be important, although fever has proved to be a relatively insensitive surrogate marker for this.7 In our study the daily prevalence of school absence (or days' data missing if at weekends) said to be due to illness (excluding accidental injury) was used as an imperfect measure of such infections and was not found to be associated with daily pollutant levels. Data missing from an individual's record due to ill health could weaken the apparent effect of pollutants if the missed days included illness precipitated or exacerbated by air pollution. The validity of the health outcome measures where children record their own data is not known and misclassification arising in this area could weaken any apparent effects of pollutants. Invented, misread, or inadequate PEF values can occur and these have been shown to increase with time.25 Less is known about the validity and accuracy of symptom responses, but these may reduce with waning interest. In addition, the low prevalence of symptom reporting, particularly in the summer, may also have reduced the sensitivity of our study.

The number of subjects enrolled in this study was greater than in some widely reported panel studies that have shown an association between  $PM_{10}$  and decrements in PEF in this age group.<sup>2-4</sup> However, these studies have exclusively examined populations selected on the basis of existing respiratory symptoms or asthma. In addition, in all these cases pollutant levels were greater than seen in this study where, in general, pollutant levels were modest in winter, though not unrepresentative of the UK, and very low in summer. It may therefore be that this study had insufficient power to detect effects in an unselected cohort of children.

In conclusion, this study does not provide evidence for day to day respiratory health effects of pollutants, including particulates and individual acid and anion species, in a panel of UK inner city primary schoolchildren or subgroups with atopy or pre-existing wheeze. However, only short term effects were considered so these results do not preclude an effect of very fine particulates or acid species on longer term changes in lung function, symptoms, or lung development. Previous authors have suggested that short term pollutant effects occur without threshold. We believe that, if such effects exist, they are likely to be marginal at these observed pollutant concentrations. It is likely that the complexity of adequately dealing with both intraindividual and interindividual variability, in addition to quantitatively small associations between population average responses and pollutants, may be beyond the modelling approach adopted by the PEACE study. Further work should concentrate on more homogeneous groups thought to be at high risk of adverse effects and attempt to improve the validity of health status monitoring.

#### ACKNOWLEDGEMENTS

This study was funded by the Department of Health, UK. The authors acknowledge the assistance of Dr G McGregor, Department of Geography, University of Birmingham, Dr John Middleton, Sandwell Health Authority, Sandwell Environmental Services, and the Pollen Research Unit, WCHE, Worcester, and thank the teachers and pupils of the five participating junior schools from Birmingham (Bromford Road, Ward End and Firs) and Sandwell (Springfield and Perryfields).

Authors' affiliations

**D J Ward, N Jones, R M Harrison, S Hussain, S Walters,** Institute of Public and Environmental Health, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK

**K T Roberts, J G Ayres,** Department of Respiratory Medicine, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK

#### REFERENCES

- 1 Brunekreef B, Dockery DW, Krzyzanowski G. Epidemiologic studies on short-term effects of low levels of major ambient air pollution components. Environ Health Perspect 1995;103(Suppl 2):3-13
- 2 Roemer W, Hoek G, Brunekreef B. Effect of ambient winter air pollution on respiratory health of children with chronic respiratory symptoms. Am Rev Respir Dis 1993:147:118-24.
- 3 Pope CA, Dockery DW, Spengler JD, et al. Respiratory health and PM<sub>10</sub> pollution. A daily time series analysis. Am Rev Respir Dis 1991;**144**:668–74.
- 4 Neas LM, Dockery DW, Koutrakis P, et al. The association of ambient air pollution with twice daily peak expiratory flow rate measurements in children. *Am J Epidemiol* 1995;**141**:111–22.
- 5 Pope CA, Dockery DW. Acute health effects of PM<sub>10</sub> pollution on symptomatic and asymptomatic children. Am Rev Respir Dis 1992;**145**:1123-8.
- 6 Hiltermann TJ, Stolk J, Van der Zee SC, et al. Asthma severity and susceptibility to air pollution. *Eur Respir J* 1998;11:686–93.
  7 Roemer W, Hoek G, Brunekreef B, *et al.* Daily variations in air pollution
- and respiratory health in a multicentre study the PEACE project. Pollution effects on asthmatic children in Europe. Eur Respir J 1998; 12:1354–61.
  Lebowitz MD. Epidemiological studies of the respiratory effects of air pollution. Eur Respir J 1996; 9:1029–54.
  Thurston GD, Ito K, Hayes CG, et al. Respiratory hospital admissions
- and summertime haze air pollution in Toronto, Ontario: consideration of the role of acid aerosols. *Environ Res* 1994;65:271-90.
- 10 Hoek G, Brunekreef B. Effects of low-level winter air pollution concentrations on respiratory health of Dutch children. Environ Res 1994;64:136-50.
- Brunekreef B, Hoek G, Roemer W, et al. Panel studies for investigating 11 the acute health effects of air pollution. *Eur Respir Rev* 1998;**8**:131–4.
- 12 Ward DJ, Miller MR, Walters S, et al. Impact of correcting peak flow for non-linear errors on air pollutant effect estimates from a panel study. Eur Respir J 2000;15:137-40.
- 13 Airborne Particles Expert Group. Source apportionment of airborne particulate matter in the United Kingdom. London: Stationery Office, 1999.

- 14 Harrison RM, Kitto AM-N. Field intercomparison of filter pack and denuder sampling methods for reactive gases and particulate pollutants. Atmos Environ 1990;24A:2633-40.
- 15 Koutrakis P, Thompson KM, Wolfson JM, et al. Determination of aerosol strong acidity losses due to interactions of collected particles: results from laboratory and field studies. Atmos Environ 1992;26A:987-95.
- 16 Koutrakis P, Wolfson JM, Spengler JD. An improved method for measurement of aerosol acidity: results from a nine month study in St Louis, MO, and Kingston, TN. Atmos Environ 1988;22:157-63.
- 17 Roemer W, Hoek G, Brunekreef B, et al. Effects of short-term changes in urban air pollution on the respiratory health of children with chronic respiratory symptoms: the PEACE project: Introduction. Eur Respir Rev 1998;8:4-11.
- 18 Roemer W, Clench-Aas J, Englert N, et al. Inhomogeneity in response to air pollution in European children (PEACE project). Occup Environ Med 1999;**56**:86-92.
- 19 Committee on the Medical Effects of Air Pollutants, Department of Health. Non-biological particles and health. London: HMSO, 1995.
- 20 Ostro BD, Lipsett MJ, Wiener MB, et al. Asthmatic responses to airborne acid aerosols. Am J Public Health 1991;81:694-702.
- 21 Boezen M, Schouten J, Rijcken B, et al. Peak expiratory flow variability, bronchial responsiveness, and susceptibility to ambient air pollution in adults. *Am J Respir Crit Care Med* 1998;1**58**:1848–54.
- 22 Boezen HM, Van der Zee SC, Postma DS, et al. Effects of ambient air pollution on upper and lower respiratory symptoms and peak expiratory flow in children. Lancet 1999;353:874-8.
- 23 Rusznak C, Devalia JL, Davies RJ. The airway response of asthmatic subjects to inhaled allergen after exposure to pollutants. Thorax 1996;51:1105-8
- 24 Timonen KL, Pekkanen J, Korppi M, et al. Prevalence and characteristics of children with chronic respiratory symptoms in eastern Finland. Eur Respir J 1995;8:1155-60
- 25 Redline S, Wright EC, Kattan M, et al. Short-term compliance with peak flow monitoring: results from a study of inner city children with asthma. Pediatr Pulmonol 1996;21:203-10.